Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device

Artivion AORT recently secured FDA premarket approval (“PMA”) for its AMDS Hybrid Prosthesis to treat acute DeBakey Type I aortic dissections with clinical or radiographic malperfusion. The approval removes the institutional review board (“IRB”) requirement tied to the device's previous Humanitaria…

Artivion AORT recently secured FDA premarket approval (“PMA”) for its AMDS Hybrid Prosthesis to treat acute DeBakey Type I aortic dissections with clinical or radiographic malperfusion. The approval removes the institutional review board (“IRB”) requirement tied to the device's previous Humanitarian Device Exemption (“HDE”), paving the way for broader adoption across U.S. hospitals.

From an investor's perspective, the approval marks an important commercial milestone for Artivion as it enables the company to more fully capitalize on an estimated $150 million annual U.S. market opportunity. With its commercial infrastructure already established following the HDE launch, the removal of administrative hurdles is expected to accelerate AMDS adoption, supporting the company's long-term growth strategy in the aortic disease market.

Likely Trend of AORT Stock Following the News

Shares of AORT have traded flat since the announcement on Monday. In the year-to-date period, shares of the company lost 50.7% compared with the industry’s 14.7% decline. The S&P 500 increased 8.9% in the same time frame.

The FDA approval of AMDS is expected to strengthen Artivion's long-term growth trajectory by expanding access to a larger patient population and removing a key adoption barrier for U.S. hospitals. With the IRB requirement no longer needed, physicians can deploy the device more readily, potentially driving higher procedure volumes and accelerating commercial adoption.

The approval also enables Artivion to fully pursue the estimated $150 million annual U.S. market opportunity while reinforcing its leadership in aortic disease treatment. Coupled with its expanding portfolio of aortic arch solutions, including the recently acquired NEXUS system and the ongoing development of ARCEVO LSA, the milestone is likely to enhance the company's competitive position and support sustained revenue growth over the long term.

AORT currently has a market capitalization of $1.09 billion.

More on the News

The approval covers patients with acute DeBakey Type I aortic dissections with clinical or radiographic malperfusion, a population that Artivion estimates accounts for roughly 60% of all DeBakey Type I aortic dissection cases. This broader regulatory clearance is expected to simplify hospital adoption and enable physicians to provide the therapy more readily to eligible patients. According to the company, approximately 6,000 patients in the United States experience acute DeBakey Type I aortic dissections each year, a life-threatening condition that requires immediate surgical intervention. Left untreated, mortality can reach nearly 50% within the first 48 hours.

The AMDS Hybrid Prosthesis is the world's first aortic arch remodeling device specifically designed for the treatment of acute DeBakey Type I aortic dissections. It is implanted alongside a standard hemiarch replacement procedure and is rapidly deployed into the aortic arch without adding meaningful technical complexity or significantly extending surgical time. Unlike conventional hemiarch repair, which primarily addresses the initial tear while leaving the downstream aorta vulnerable to future complications, AMDS stabilizes the aortic arch, promotes favorable aortic remodeling and helps eliminate distal anastomotic new entry (“DANE”) tears.

By preserving the patient's native aortic arch, the device also allows physicians to perform minimally invasive endovascular reinterventions, if required, instead of more complex open arch reconstruction procedures. This approach has the potential to improve long-term patient outcomes while reducing the likelihood of repeat invasive surgeries.

The PMA approval was supported by data from the PERSEVERE U.S. IDE trial involving 93 patients. At the 30-day mark, AMDS demonstrated a 72% reduction in all-cause mortality and a 54% reduction in major adverse events, including stroke, renal failure requiring dialysis and myocardial infarction, compared with the current standard-of-care hemiarch procedure.

Notably, the trial reported zero DANE tears, a common complication following conventional hemiarch repair that often increases the risk of future reinterventions. Two-year follow-up data presented earlier this year further reinforced the device's durability, showing no new DANE tears, no additional unanticipated aortic reoperations, stable aortic dimensions and continued expansion of the true lumen across multiple aortic zones.

Favorable Industry Prospect for AORT

Per a report by Grand View Research, the global aortic aneurysm market size was valued at $5 billion in 2025 and is projected to grow from $5.6 billion in 2026 to $12.9 billion by 2033, at a CAGR of 12.6% from 2026 to 2033.

The market growth is driven by the increasing prevalence of aortic aneurysms, fueled by aging populations and common risk factors such as hypertension, smoking and atherosclerosis.

A Recent Development by AORT

In May, AORT completed the acquisition of its long-standing partner Endospan Ltd., a pioneer in the endovascular repair of aortic arch disease and developer of the NEXUS Aortic Arch System. Artivion utilized its previously drawn $150 million delayed draw term loan to fund the $135 million upfront net purchase price for Endospan. The transaction also includes potential additional consideration contingent on commercial performance.

AORT’s Zacks Rank & Key Picks

Currently, AORT carries a Zacks Rank #4 (Sell).

Some better-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and Intuitive Surgical ISRG.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

West Pharmaceutical, currently flaunting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report